FDA has approved sacituzumab govitecan (Trodelvy) for the treatment of triple-negative breast cancer that has spread to other parts of the body. Under the approval, patients must have already undergone at least two prior treatment regimens.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2B4OjEo
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2B4OjEo